Silexion Therapeutics (SLXN) Change in Cash (2023 - 2026)

Silexion Therapeutics' Change in Cash history runs 4 years deep, the most recent figure standing at -$3.6 million for Q1 2026.

• In Q1 2026, Change in Cash fell 171.65% year-over-year to -$3.6 million; the TTM figure through Mar 2026 stood at -$3.7 million (down 209.13% YoY), while the FY2025 annual figure was $4.8 million, up 245.05% from the prior year.
• Change in Cash for Q1 2026 stood at -$3.6 million, down from -$3.2 million in the prior quarter.
• The five-year high for Change in Cash was $5.8 million in Q3 2025, with the low at -$3.6 million in Q1 2026.
• The 4-year median for Change in Cash is -$1.1 million (2023), against an average of -$425000.0.
• Peak annual rise in Change in Cash reached 2203.19% in 2025, while the deepest fall reached 337.2% in 2025.
• Silexion Therapeutics' Change in Cash stood at -$1.3 million in 2023, then jumped by 41.16% to -$742000.0 in 2024, then slumped by 337.2% to -$3.2 million in 2025, then retreated by 9.83% to -$3.6 million in 2026.
• Business Quant data shows SLXN's Change in Cash at -$3.6 million in Q1 2026, -$3.2 million in Q4 2025, and $5.8 million in Q3 2025.